Similarly, in a cohort of 371 STAD patients, those with higher expression had a median overall survival of 46.9 months, whereas those with lower SMYD4 expression had a median overall survival of 21.1 months (HR = 0.66, 95% CI = 0.47–0.91; p = 0.011) (Figure 6B). Here, SMYD4 is linked to gastric adenocarcinoma.